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Recent studies demonstrate that statins decrease ventricular arrhythmias in internal cardioverter deﬁbrillator (ICD) patients.
The mechanism is unknown, but evidence links increased inﬂammatory and oxidative states with increased arrhythmias. We
hypothesized that statin use decreases oxidation. Methods. 304 subjects with ICDs were surveyed for ventricular arrhythmia. Blood
was analyzed for derivatives of reactive oxygen species (DROMs) and interleukin-6 (IL-6). Results. Subjects included 252 (83%)
men, 58% on statins, 20% had ventricular arrhythmias. Average age was 63 years and ejection fraction (EF) 20%. ICD implant
duration was 29 ± 27 months. Use of statins correlated with lower ICD events (r = 0.12, P = .02). Subjects on statins had
lower hsCRP (5.2 versus 6.3; P = .05) and DROM levels (373 versus 397; P = .03). Other factors, including IL-6 and EF did
not diﬀer between statin and nonstatin use, nor did beta-blocker or antiarrhythmic use. Multivariate cross-correlation analysis
demonstrated that DROMs, statins, IL-6 and EF were strongly associated with ICD events. Multivariate regression shows DROMs
to be the dominant predictor. Conclusion. ICD event rate correlates with DROMs, a measure of lipid peroxides. Use of statins is
associated with reduced DROMs and fewer ICD events, suggesting that statins exert their eﬀect through reducing oxidation.
1.Background
Sudden Cardiac death (SCD) accounts for over 400000
deaths per year [1] in the United States, more than 50%
of all cardiac related death. Ventricular arrhythmias cause
most of these deaths [2]. The only treatment for ventricular
arrhythmias with proven mortality beneﬁt is the internal
cardioverter-deﬁbrillator (ICD). Two recent observational
trials have demonstrated that Hydroxymethylglutaryl coen-
zyme A reductase inhibitors (statins) decrease the incidence
of ventricular arrhythmias as well as increase survival in
patientswithICDs[3,4].Thissurvivalbeneﬁtexists forboth
ischemic (MADITII) and non-ischemic cardiomyopathies
(DEFINITE) and the reduction in ICD discharges is inde-
pendent of statins’ cholesterol-lowering eﬀects.
One proposed mechanism for the antiarrhythmic eﬀect
of statins is their antioxidant properties [3]. Statins reduce
the generation of reactive oxygen species by inhibition of
vascular NAD(P)H oxidase [5, 6], inhibiting the respiratory
burst of phagocytes [7], antagonizing the prooxidant eﬀect
of angiotensin II and endothelin-1 [8], and increasing the
synthesis of vascular nitric oxide [9, 10]. In addition, some
statins and their metabolites are direct free radical scav-
engers. As inﬂammation is closely linked to the production
of reactive oxygen species (ROS), statins may also have
important antiinﬂammatory eﬀects. The molecular basis of
these observed antiinﬂammatory eﬀects of statins may relate
to their ability block the production and/or activity of ROS
[11].
Several lines of evidence link oxidative stress with
arrhythmias [12–14]. H2O2, a form of oxidative stress,
increases ventricular arrhythmias through alterations in
cellular electrophysiology reducing sodium channel current
and preventing its complete inactivation. The resultant
persistentcurrentduringtheactionpotentialplateauappears
to be the result of lipid peroxidation [15]. Patch clamp2 Cardiology Research and Practice
experiments in rat myocytes have also observed a H2O2-
induced augmentation of sodium current via a slowing of
the inactivation kinetics, producing a marked prolongation
of the cellular action potential [16]. This provides strong
evidence that statins act to reduce arrhythmic risk by reduc-
ing lipid peroxidation. Thus we hypothesized that statin
medications decrease ventricular arrhythmias by reducing
oxidative stress. To test this hypothesis, we compared serum
measures of oxidation in the lipid and soluble phases in
patients at high arrhythmic risk. This population includes
bothpatientsthatweretakingstatinsandthosethatwerenot,
providing a direct measure of the antioxidant eﬀects due to
statin use.
2. Methods
To select patients at high risk for ventricular arrhythmia,
we retrospectively examined patients undergoing either ICD
implantationorICDgeneratorexchange.Thisstudyprotocol
was approved by the Emory University Internal Review
Board. These patients were enrolled in the Genetic Risk
Assessment for Deﬁbrillator Events (GRADE) trial, and were
undergoing new ICD implantation or who had undergone
ICD placement or generator exchange within the last 5 years
in one of the four Emory University Hospitals. Patients
met the inclusion criteria of being age 18 or older, able to
give informed consent and having a depressed left ventric-
ular ejection fraction (LVEF) of <30%. Exclusion criteria
included patient refusal, patients with a life expectancy less
than 6 months, patients who had ongoing class IV heart
failure symptoms, patients who were post-cardiac transplant
or with left ventricular assist devices. Demographic and
medical information obtained on enrollment included: age,
gender, race, history of smoking, medications, New York
Heart Association (NYHA) class, etiology of heart disease,
hypercholesterolemia, history of myocardial infarction (MI)
history of coronary artery bypass (CABG) surgery, family
history of heart disease, history of arrhythmias, history
of syncope, echocardiogram results, cardiac catheterization
results, nuclear imaging results, electrocardiograms, blood
pressure, heart rate, electrolytes and date of ICD implanta-
tion surgery and any ICD generator exchanges.
2.1. Biomarker Data. A single blood draw was performed
at the time of enrollment and analyzed for markers of
oxidative stress and inﬂammation in the Emory Biomarkers
Core Laboratory. Markers used to measure oxidative stress
were: ratios of oxidized to reduced glutathione (Eh GSH)
and cystiene (Eh CySH) in plasma (thiol ratios) [17]a n d
derivatives of reactive oxygen species (DROMs) [18, 19].
Detailed methods to prevent rapid oxidation of samples
have been delineated previously [20]. Blood was collected
from an antecubital vein and transferred immediately to a
micro-centrifuge tube containing 0.5mL of a preservation
solution of 100mM serine·borate (pH 8.5) containing (per
mL) 0.5mg sodium heparin, 1mg bathophenanthroline
disulfonate sodium salt, and 2mg iodoacetic acid. Use of this
procedure minimizes auto-oxidation and hemolysis [20].
All blood was drawn between 7:30 am and 3:00 pm in
non-fasting patients. Following centrifugation to remove
blood cells, aliquots (200μL) were transferred to tubes con-
taining200μLof10%(w/v)perchloricacidcontaining0.2M
of boric acid and 10μM γ-Glu-Glu as internal standard.
Samples were stored at −80
◦C( <2 months) prior to further
processing to form N-dansyl derivatives and analysis by
HPLC with ﬂuorescence detection. Reduced glutathione,
cystine, and cysteine levels in plasma were greater than 1,000
times the level of detection (∼1nM). Oxidized glutathione
levels were approximately 10 times this limit. Previous data
have shown stable measurements over this length of storage
[20]. Metabolites were identiﬁed by coelution with stan-
dards, and quantiﬁed by integration relative to the internal
standard.
We calculate the redox states (Eh) of the thiol/disulﬁde
pools using the Nernst equation, Eh = Eo + RT/nF ln
[disulﬁde]/[thiol]2. Eo is the standard potential for the
redox couple, R is the Rydberg constant, T is the absolute
temperature, n is 2 for the number of electrons transferred,
and F is Faraday’s constant. The standard potential E o used
for the glutathione and cystiene redox couples was −264mV
and −250mV, respectively [20]. Less negative Eh numbers
imply a more oxidized state. DROMs were measured in Carr
units with higher values indicating higher levels of oxidative
stress. DROMs (Diacron International, Grosseto, Italy) and
inﬂammatory markers, high sensitivity C-reactive protein
(hsCRP; Life Diagnostics, West Chester, PA), interleukin-1-
β (IL-1β; R&D Systems, Minneapolis, MN), interleukin-6
(IL-6; R&D Systems), and tumor necrosis factor α (TNFα;
R&D Systems), were measured using commercially available
kits. The intraassay coeﬃcients of variation (%CV) were Eh
GSH, <1a t−156mV and <1a t−120mV; Eh CySH, 5.0 at
−100mV and 4.5 at −60mV; DROMs, 2.2 at 300 Carr units
and 2.3 at 550 Carr units; IL-1β, 10.1 at 0.2pg/mL and 5.2
at 10pg/mL; hsCRP 5.1 at 1μg/ml and 3.6 at 8μg/mL; IL-
6, 20.9 at 3.2pg/mL and 6.2 at 50pg/mL; and TNFα, 11.9 at
2pg/mL and 7.3 at 50pg/mL.
2.2. Ventricular Arrhythmias. Events were identiﬁed through
routine device interrogations and chart review. All history
of appropriate therapies for ventricular ﬁbrillation (VF) or
ventricular tachycardia (VT) were recorded. Dates, times,
types and number of therapies were all documented. There
was no standardization of ICD programming due to the
study design; some patients had antitachycardia pacing
(ATP) programmed on while others did not. Thus both ATP
and shock therapies were recorded (henceforth referred to as
“ICD events”). Independent cardiologists adjudicated thera-
piesaseitherappropriatetherapyforventriculararrhythmias
or inappropriate therapy, for a non-VT/VF. However, as
this was a retrospective study, the original strips were not
always available in the medical chart and we were unable
to re-adjudicate ventricular arrhythmias and had to rely
on the original adjudications. Only appropriate therapies
documented to be for ventricular arrhythmias were included
in the analysis.
2.3. Data Analysis. Statistical analysis was performed using
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60606). Baseline characteristics of patients who received
and did not receive ICD therapies were compared using a
paired t-test for continuous variables (expressed as mean
± SD) and Fisher’s exact test for categorical variables.
Marker data were presented as the mean ± SD, except as
noted. In comparing biomarker data based on presence or
absence of statin use, we employed the standard t-test for
equality of means. All statistical tests were two-tailed with
signiﬁcance taken to be P ≤ .05. Patient characteristics and
all oxidative and inﬂammatory markers were examined for
links to ICD events using Pearson’s correlation coeﬃcients.
Multivariate models were used to examine the association
between each oxidative marker and the occurrence of ICD
therapies while controlling for other inﬂammatory markers
and signiﬁcant characteristics. Due to the wide range of
follow up times, events were examined as a function of time,
in “events/months.”
3. Results
304 patients were enrolled and had blood tests performed
and received at least 3 months of follow up (range: 3
to 135 months, mean 29 months). Table 1 presents their
demographic data. There were 252 men (83%) and 52
women (17%). Average age was 63 ± 11, EF 20% ± 7%, 114
(38%) had diabetes, 175 (58%) were on statins, 246 (80%)
were on beta-blockers, 61 (20%) were on antiarrhythmics,
236 (77%) had no ICD therapies, 200 (67%) were smokers
and 96 (65%) had coronary artery disease (CAD). Other
medication use examined included ACE-inhibitors (177,
58%), ARBs (71, 23%) and PPARs (28, 9%), all of which
are known to aﬀect oxidative stress. Mean biomarker values
werehighforallpatients(Table 1).Table 2 compares patients
using statins to those who were not using statins. Statin
users showed signiﬁcant diﬀerences in incidence of CAD
(P<. 01) and cigarette smoking (P = .01). Note however,
that cigarette smoking correlates directly with CAD and is
not an independent variable. Statin users also had signiﬁcant
reductions in DROM and hsCRP. Figure 1 shows EF, hsCRP,
DROM and IL-6 by statin use. Table 3 provides the Pearson
correlation coeﬃcients and P values for the characteristics
that correlated with ICD therapy events. Ejection fraction,
IL-6 levels, statins, and DROMs each were signiﬁcant.
Figure 2 shows the relationship between statin use and ICD
events.
Multivariate cross-correlation analysis conﬁrms the sig-
niﬁcant relationships of IL-6, DROMs, statins and EF with
events. For IL-6: P = .024, Pearson coeﬃcient of 0.124;
DROM: P = .001, Pearson coeﬃcient of 0.183; statins:
P = .047, Pearson coeﬃcient of −.107 ; TNF-α: P = .040,
Pearson coeﬃcient of −0.112; and EF: P = .015, Pearson
coeﬃcient of −0.132. Multivariate linear regression shows
DROMs to be the dominant predictive factor of events, with
a regression coeﬃcient of 0.164 (P = .026). Beta-blockers
and antiarrhythmic medications were also examined in the
multivariate analysis and were not found to be signiﬁcant,
beta-blockers had a Pearson coeﬃcient of −0.037 (P = .54)
and antiarrhythmics had a Pearson coeﬃcient of 0.062 (P =
.29).
Table 1
Baseline demographics
Age 62 ± 12
Gender 252 men (83%)
CAD 196 (65%)
DM 114 (38%)
ICD therapies 68 (23%)
Average EF 20% ±7%
Statins 175 (58%)
Beta-blockers 246 (81%)
Antiarrhythmics 61 (20%)
Smokers 202 (67%)
Aﬁb 87 (29%)
ACE 177 (58%)
ARB 71 (23%)
PPAR 28 (9.2%)
Biomarker Value
CRP 5.7 ± 4.67
IL-6 4.3 ± 3.2
IL1β 0.52 ± 0.37
TNF-α 4.4 ± 2.8
DROM 383 ± 95
Eh G −126 ± 13
Eh C −66 ± 9
Table 2
Statin Use (175) No Statin Use (129) P
Age 59 ± 13 65 ± 9. 0 0
Male 146 (83%) 106 (82%) .46
DM 101 (57%) 40 (31%) .055
Smokers 127 (72%) 75 (58%) .01
CAD 138 (78%) 58 (45%) .00
EF 20 ± 7% 19 ± 7% .51
Beta-blocker 138 (79%) 105 (81%) .25
Antiarrhythmic 30 (17%) 31 (24%) .11
Aﬁb 53 (30%) 50 (29%) .87
CRP 5.2 ± 4.4ug/ml 6.3 ± 5.0ug/ml .05
DROM 373 ± 87Carr 397 ± 102Carr .03
IL-β 0.52 ± 0.37pg/ml 0.53 ± 0.36pg/ml .90
IL-6 4.3 ± 3.4pg/ml 4.5 ± 3.0pg/ml .88
TNF-α 4.5 ± 3.0pg/ml 4.3 ± 2.6pg/ml .64
Eh G −126 ± 12mV −126 ± 13mV .82
Eh C −66 ± 9mV −67 ± 9mV .87
4. Conclusions
For these high risk patients, we demonstrate that DROM,
IL-6 and statins are correlated with decreased ICD event
rates. Interestingly, statin use decreased DROM but not
IL-6, suggesting IL-6 aﬀects event rates via a separate
mechanism. However, DROMs were the dominant predictor
of event rate, leaving statin use the primary diﬀerence
in rate reduction. To further validate our data set, we4 Cardiology Research and Practice
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Figure 1: Comparison of mean DROM, CRP, IL-6 and EF by statin use or non-use with respective P values. Statin use = 1, non-use = 0.
Table 3
ICD events∗ Pearson’s Correlation Coeﬃcient P value
Age −0.058 .37
Gender −0.033 .57
DM 0.052 .37
Cigs 0.079 .17
CAD 0.37 .52
EF −0.120 .04
Beta-Blocker −0.037 .54
AntiArrhythmic 0.062 .29
CRP 0.057 .37
DROM 0.188 .003
IL-6 0.129 .043
IL-β −0.065 .30
TNF-α −0.111 .08
EhGSH 0.064 .32
EhCYS -0.005 .94
Statin −0.114 .037
∗Analysis by event-months.
conﬁrm the previous observation that statin medication use
correlates with decreased rates of ventricular arrhythmias
as measured by ICD therapies and the independence of
ejection fraction as a risk factor for ventricular arrhythmias.
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Figure 2: Comparison of events (any events = 1 versus no events =
0) by statin use (= 1) or non-use (= 0). Patients on statins are less
likely to experience ICD events.
When we examined biomarkers to assess inﬂammation and
oxidative stress burden, we found that hsCRP and DROM
were decreased in the statin users group and that IL-6 andCardiology Research and Practice 5
DROMScorrelatewitheventrisk.IL-6correlateswithevents,
but not with statin use, suggesting that IL-6 is unaﬀected
by statin use. The only factor dependent on statin use
and associated with decreased ICD events is DROM. That
DROMs are the single most predictive indicator of future
events, coupled with their statin correlation, provides strong
evidence that the mechanism by which statins lower rates of
ventricular arrhythmias is via their antioxidant eﬀect.
5. Discussion
Each patient considered had cardiac disease that qualiﬁed
them for an ICD, giving them a high risk for ventricu-
lar arrhythmias. Our patient demographics do not diﬀer
signiﬁcantly from those in the two large trials, previously
cited, which demonstrate decreased ICD events with statins.
Average patient age, gender, EF, rates of diabetes, and rates
of ACE/ARB use were all similar. Perhaps unsurprisingly,
ad i ﬀerence was seen in the rates of cigarette smokers. In
the ischemic cardiomyopathy group (MADITII), the rate of
smoking was 81%, in the non-ischemic group (DEFINITE),
38% were smokers. In our mixed ischemic and non-ischemic
population, 67% of patients were smokers. Of our smokers,
76%hadCAD(and73%ofourCADpatientsweresmokers).
Our patients’ biomarkers are elevated. Elevated inﬂam-
matory markers and markers of oxidative stress have been
correlated with increased mortality in cardiac disease.
hsCRP, for example, is considered a “high risk” marker
(per AHA/CDC consensus document) [21] when the levels
are >3.0mg/dl. Our mean value was 5.7. In a study
recently accepted for publication, we compare case-matched
biomarkers for patients with and without atrial ﬁbrillation.
In that study we demonstrate that patients with AF are more
oxidized compared to the controls. These ICD patients are
similarly oxidized when compared our AF patients: DROMS
are similar at 388 versus 383 Carr units, Eh C −66 versus
−68mV, Eh G −126 versus −133mV. For our inﬂammatory
markers hsCRP is higher (5.7 versus 3.9uGu/ml), as is
IL-6 (5.5 versus 4.3pg/ml), TNFα is lower 4.4 versus
6.4pg/ml, and IL-1β, was the same 0.5 versus 0.5pg/ml.
“Normal” values are age and disease state-dependent, but for
perspective, the case-matched controls with no arrhythmias
in our atrial ﬁbrillation study had mean DROMS 310 Carr
units, Eh CySH −77mV, Eh GSH −154mV, IL-1β 0.4pg/mL,
IL-6 3.9pg/mL, TNFα 5.5pg/mL, and hsCRP 3.6μg/mL.
In these high-risk patients, statin use correlates with
decreased arrhythmia risk. Decreases in DROMs correlate
with decreased ICD events, and with statin use. This suggests
that statin use decreases ventricular arrhythmias in part
due to its antioxidant properties, possibly via ion channel
alterations.
ThatIL-6does notchangewithstatinusehasbeensome-
what controversial in the literature. It has been previously
documented to be unchanged with pravastatin, simvastatin,
and atorvastatin in several studies [22–24]. Others, however,
have seen a change in Il-6 with statin use [25]. As IL-6 is
known to exhibit great circadian variation, this particular
marker may be more sensitive to the variable followup time
courses in our study. However, the lack of correlation with
statin use further suggests that statins are acting through an
IL-6 independent mechanism.
Measuring oxidative stress in humans is diﬃcult because
free radicals are reactive and thus short-lived. Products
of free radical damage to DNA proteins and lipids may
provide such markers. Additionally, measurements of O2-
generating enzymes can be easily quantiﬁed. We chose
several markers to examine, quantifying thoi-disulﬁde redox
couples, reduced and oxidized glutathione disulﬁde, and
cystiene/cystine ratios. These redox states represent plasma
oxidation state. To reﬂect the lipid compartment, we used
a measure of plasma lipid peroxides known as the DROMS
test. The positive correlation of reduced ICD events with
DROMS may reﬂect changes in the lipid compartment, as
opposed to the other markers of oxidative stress, which
reﬂect changes in plasma oxidative stress. This ﬁnding
demonstrates that the tissue oxidative state and the plasma
oxidative state are not necessarily equivalent. That DROMS
reﬂect the tissue state, and are signiﬁcant is further cir-
cumstantial evidence to support a tissue-level mechanistic
change.
The mechanisms whereby oxidative stress may con-
tribute to ventricular arrhythmias are unknown, but there
is evidence that oxidants can aﬀect ion channel activity
[26]. Recently, we have shown that the cardiac sodium
channel (SCN5a) promoter region contains an NF-κB
response element that could lead to Na+ channel tran-
scriptional regulation by a NF-κB-dependent mechanism
[27].
Much further research is needed to answer these ques-
tions. A prospective examination of the association between
oxidative stress markers and ventricular arrhythmias is
necessary. Such a prospective study of change in oxidative
stress markers in the presence of statin use correlating to
decreased ventricular arrhythmias is also warranted.
5.1. Limitations. As with all retrospective studies, several
limitations exist. The most signiﬁcant limitation is that we
had no consistent time correlation between of our data
points; follow up ranged from 3 months to 11 years. There
was no correlation between the time of the blood draw for
biomarkers and the arrhythmic events. The blood draw was
done at the time of enrollment in the study and a patient
undergoing generator exchange could have had ICD events
thatwerelongbeforetheblooddrawwastaken.Twentythree
percent of our patients experienced ICD events. However,
these events could have occurred anytime within 5 years
of the blood draw. This weakens the connection between
the biomarkers and ventricular events. That statistically sig-
niﬁcant associations remain despite this limitation suggests
that the association is strong. We measured marker levels
during usual clinical hours and without fasting, mimicking
the most common clinical scenario. Measuring at other
times or conditions may aﬀect the results, but there is no
known diurnal variation in DROM levels, or hsCRP levels.
T h e r ed o e sa p p e a rt ob ed i u r n a lv a r i a t i o no fp l a s m ar e d u c e d
thiols related to meals in animals [28], but the eﬀect of
this variation on the ratio of oxidized to reduce thiols
is unknown. In preliminary studies, diurnal variations in6 Cardiology Research and Practice
Eh GSH and Eh CySH were small, and have peaks in that are
separated by 6–7hr.
Non-uniformity in ICD programming is another sig-
niﬁcant limitation. Some patients were programmed as a
“shock box”, meaning they would only receive ICD therapy
for fast VT or VF, with heart rates in the range of 200+
beats per minute (BPM). Other patients had VT zones set
as low as 160BPM, and may have received therapies (ATP or
shock) for slower VT. The rate of VT, however, is an artiﬁcial
distinction.Morepatientsmayhaveexperienced“ventricular
arrhythmias” if all patients had an ATP zone programmed.
Contrariwise, fewer patients may have received therapy if all
patients had been set up as a shock only ICD. This may have
shifted a signiﬁcant number of patients into or out of the
therapy group.
Another inconsistency was the lack of quantiﬁcation of
the dose, type, and duration of statin therapy. Our data
points are simply binary, indicating statin use or no statin
use. Patients were listed as taking statin medications if they
were taking any statin medication at the time of study
enrollment. If they had been taking a statin for 5 years, but
had stopped it the week before enrollment, these patients
would be considered as not on a statin. By contrast, patients
starting a statin the week prior to enrollment would have
been considered as on a statin. We also treat all statin
medication types and doses equivalently. Previous studies
have noted a “dose eﬀect” of statins [3], and the both the
question of dose-response and time-dependent dosing are
not accounted for in our model.
These limitations aside, our result is both interesting and
thought-provoking. This result provides both a motivation
forandajumpingoﬀpoint toplanningfuturetrialstoclarify
the relationship between statins and arrhythmic events.
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